

## BIOTOSCANA INVESTMENTS S.A.

Corporate Taxpayer's ID (CNPJ/ME): 19,688,956/0001-56  
L-1470 Luxembourg, 70 route d'Esch, Grand-Duché de Luxembourg  
Legal representative in Brazil: Av. dos Imarés, 401, São Paulo, SP

## NOTICE TO THE MARKET 1Q20 RESULTS RELEASE DATE

BIOTOSCANA INVESTMENTS S.A. ("**Company**" or "**GBT**") (B3: GBIO33), a leading biopharmaceutical company in Latin America, hereby informs that, in the current context of the COVID-19 pandemic, it intends to release the quarterly results regarding the first quarter of 2020 on June 26 , 2020, pursuant to the CVM Deliberation n.º 849, of March 31, 2020.

The Calendar of Events is also available in the Company's IR website.

Montevideo, May 28, 2020

**BIOTOSCANA INVESTMENTS S.A.**

Claudio Coracini  
Legal Representative in Brasil

### About GBT Grupo Biotoscana

GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT's strong portfolio combines world-class licenses and proprietary products. To find out more, please visit [www.grupobiotoscana.com](http://www.grupobiotoscana.com).